Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

2015

Bone Therapeutics Appoints Thomas Lienard as Chief Business Officer

  • Read more about Bone Therapeutics Appoints Thomas Lienard as Chief Business Officer

Bone Therapeutics’ ALLOB® receives Orphan Drug Designation for Osteogenesis Imperfecta from the EMA and FDA

  • Read more about Bone Therapeutics’ ALLOB® receives Orphan Drug Designation for Osteogenesis Imperfecta from the EMA and FDA

Bone Therapeutics Provides Business Update for the Third Quarter of 2015

  • Read more about Bone Therapeutics Provides Business Update for the Third Quarter of 2015

Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects

  • Read more about Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects

ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference

  • Read more about ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference

Bone Therapeutics completes recruitment of the first half of patients in ALLOB® Phase IIA spinal fusion trial

  • Read more about Bone Therapeutics completes recruitment of the first half of patients in ALLOB® Phase IIA spinal fusion trial

Bone Therapeutics announces its financial calendar for 2016

  • Read more about Bone Therapeutics announces its financial calendar for 2016

Pagination

  • Previous page ‹‹
Subscribe to 2015
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions